Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
about
Samarium for osteoblastic bone metastases and osteosarcomaTreatment options in androgen-independent prostate cancer.Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.Metabolism and pharmacokinetics of radium-223 in prostate cancer.Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy.
P2860
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
description
1992 nî lūn-bûn
@nan
1992 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
@ast
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
@en
type
label
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
@ast
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
@en
prefLabel
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
@ast
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
@en
P2093
P1433
P1476
Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.
@en
P2093
P304
P356
10.1016/S0936-6555(05)81078-7
P577
1992-05-01T00:00:00Z